Anticholinergic Drugs in Geriatric Psychopharmacology

被引:79
|
作者
Lopez-Alvarez, Jorge [1 ,2 ]
Sevilla Llewellyn-Jones, Julia [3 ,4 ]
Aguera-Ortiz, Luis [1 ,2 ,5 ,6 ]
机构
[1] Hosp 12 Octubre, imas12, Serv Psiquiatria, Madrid, Spain
[2] Hosp 12 Octubre, imas12, Inst Invest, Madrid, Spain
[3] Hosp Clin San Carlos, Inst Psiquiatria & Salud Mental, Madrid, Spain
[4] Hosp Clin San Carlos, Inst Invest IdISSC, Madrid, Spain
[5] Minist Sci & Innovat, Ctr Invest Biomed Red Salud Mental, Madrid, Spain
[6] Univ Complutense Madrid, Fac Med, Dept Med Legal Psiquiatria & Patol, Madrid, Spain
关键词
anticholinergic drugs; elderly; potentially inappropriate prescriptions; adverse effects; cognition; dementia; MILD COGNITIVE IMPAIRMENT; OLDER-ADULTS; BURDEN INDEX; MEDICATION USE; CHOLINESTERASE-INHIBITORS; RISK SCALE; FUNCTIONAL STATUS; ADVERSE OUTCOMES; ASSOCIATION; MEMORY;
D O I
10.3389/fnins.2019.01309
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Drugs with anticholinergic action are widely prescribed in the elderly population due to their potential clinical benefits. However, these benefits are limited by adverse effects which may be serious in particular circumstances. This review presents different aspects of the use of anticholinergics in old age with a focus in psychogeriatric patients. We critically review published data on benefits and disadvantages of anticholinergics, which are often controversial. Prevalence, pathophysiology and measurement methods of the anticholinergic action of drugs are discussed. We also present the most important drawbacks resulting from its use, including effects on cognition in healthy and cognitively impaired people, in aged schizophrenia patients, emergence of delirium and psychiatric symptoms, influence in functionality, hospitalization, institutionalization and mortality, and the potential benefits and limitations of their discontinuation. Finally, we suggest practical recommendations for the safe use of anticholinergics in clinical conditions affecting elderly patients, such as dementia, schizophrenia and acute hallucinatory episodes, depression, anxiety, Parkinson's disease, cardiovascular conditions and urinary incontinence.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Effect of anticholinergic drugs on cognitive impairment in the elderly
    Lopez-Alvarez, Jorge
    Zea Sevilla, Maria Ascension
    Agueera Ortiz, Luis
    Fernandez Blazquez, Miguel Angel
    Valenti Soler, Meritxell
    Martinez-Martin, Pablo
    REVISTA DE PSIQUIATRIA Y SALUD MENTAL, 2015, 8 (01): : 35 - 43
  • [2] Anticholinergic drugs use and risk of hip fracture in geriatric patients
    Kose, Eiji
    Hirai, Toshiyuki
    Seki, Toshiichi
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2018, 18 (09) : 1340 - 1344
  • [3] Inappropriate anticholinergic drugs prescriptions in older patients: analysing a hospital database
    Ferret, Laurie
    Ficheur, Gregoire
    Delaviez, Emeline
    Luyckx, Michel
    Quenton, Sophie
    Beuscart, Regis
    Chazard, Emmanuel
    Beuscart, Jean-Baptiste
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 94 - 100
  • [4] Anticholinergic Burden of Geriatric Ward Inpatients
    Wilczynski, Krzysztof
    Gorczyca, Marta
    Golebiowska, Jagna
    Szewieczek, Jan
    MEDICINA-LITHUANIA, 2021, 57 (10):
  • [5] Relationships Between a New Cultured Cell-Based Serum Anticholinergic Activity Assay and Anticholinergic Burden Scales or Cognitive Performance in Older Adults
    Chandramouleeshwaran, Susmita
    Ahsan, Naba
    Raymond, Roger
    Nobrega, Jose N.
    Wang, Wei
    Fischer, Corinne E.
    Flint, Alastair J.
    Herrmann, Nathan
    Kumar, Sanjeev
    Lanctot, Krista
    Mah, Linda
    Mulsant, Benoit H.
    Pollock, Bruce G.
    Rajji, Tarek K.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2021, 29 (12) : 1239 - 1252
  • [6] Measuring anticholinergic exposure in patients with dementia: A comparative study of nine anticholinergic risk scales
    Turro-Garriga, Oriol
    Calvo-Perxas, Laia
    Vilalta-Franch, Joan
    Blanco-Silvente, Lidia
    Castells, Xavier
    Capella, Dolors
    Garre-Olmo, Josep
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2018, 33 (05) : 710 - 717
  • [7] Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis
    Pieper, Nina T.
    Grossi, Carlota M.
    Chan, Wei-Yee
    Loke, Yoon K.
    Savva, George M.
    Haroulis, Clara
    Steel, Nicholas
    Fox, Chris
    Maidment, Ian D.
    Arthur, Antony J.
    Myint, Phyo K.
    Smith, Toby O.
    Robinson, Louise
    Matthews, Fiona E.
    Brayne, Carol
    Richardson, Kathryn
    AGE AND AGEING, 2020, 49 (06) : 939 - 947
  • [8] Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors
    Robinson, M.
    Rowett, D.
    Leverton, A.
    Mabbott, V.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 (08) : 659 - 664
  • [9] Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence
    Collamati, Agnese
    Martone, Anna Maria
    Poscia, Andrea
    Brandi, Vincenzo
    Celi, Michela
    Marzetti, Emanuele
    Cherubini, Antonio
    Landi, Francesco
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2016, 28 (01) : 25 - 35
  • [10] Drugs with anticholinergic properties: a potential risk factor for psychosis onset in Alzheimer's disease?
    Cancelli, Iacopo
    Beltrame, Massimiliano
    D'Anna, Lucio
    Gigli, Gian Luigi
    Valente, Mariarosaria
    EXPERT OPINION ON DRUG SAFETY, 2009, 8 (05) : 549 - 557